Codexis, Inc. (CDXS)
NASDAQ: CDXS · Real-Time Price · USD
2.270
+0.040 (1.79%)
Apr 23, 2025, 4:00 PM EDT - Market closed
Company Description
Codexis, Inc. provides enzymatic solutions for therapeutics manufacturing, leveraging its proprietary CodeEvolver technology platform to discover, develop, and enhance novel enzymes in the United States, Canada, Latin America, Europe, the Middle East, Africa, Australia, New Zealand, Southeast Asia, and China.
The company develops its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route.
It has a license agreement with Aldevron LLC and Pfizer Inc. The company was incorporated in 2002 and is headquartered in Redwood City, California.
Codexis, Inc.
| Country | United States |
| Founded | 2002 |
| IPO Date | Apr 22, 2010 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 188 |
| CEO | Stephen Dilly |
Contact Details
Address: 200 Penobscot Drive Redwood City, California 94063 United States | |
| Phone | 650 421 8100 |
| Website | codexis.com |
Stock Details
| Ticker Symbol | CDXS |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001200375 |
| CUSIP Number | 192005106 |
| ISIN Number | US1920051067 |
| Employer ID | 71-0872999 |
| SIC Code | 2860 |
Key Executives
| Name | Position |
|---|---|
| Dr. Stephen George Dilly MBBS, Ph.D. | President, Chief Executive Officer and Chairman |
| Kevin Norrett M.B.A., M.S. | Chief Operating Officer |
| Dr. Alison Moore Ph.D. | Chief Technology Officer |
| Georgia L. Erbez | Chief Financial Officer |
| Carrie McKim | Director of Investor Relations |
| Karen Frechou-Armijo | Senior Vice President and Head of Human Resources |
| Dr. Stefan Lutz Ph.D. | Senior Vice President of Research |
| John Schiffhauer | Senior Vice President of Intellectual Property |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 9, 2025 | 8-K | Current Report |
| Mar 31, 2025 | 8-K | Current Report |
| Feb 27, 2025 | 10-K | Annual Report |
| Feb 27, 2025 | 8-K | Current Report |
| Jan 16, 2025 | 8-K | Current Report |
| Nov 14, 2024 | SCHEDULE 13G/A | Filing |
| Nov 12, 2024 | 8-K | Current Report |
| Oct 31, 2024 | 10-Q | Quarterly Report |
| Oct 31, 2024 | 8-K | Current Report |
| Oct 22, 2024 | 8-K | Current Report |